Merck's Clesrovimab Shows Promise in RSV Prevention for Infants

Merck has announced an interim analysis of a clinical trial evaluating clesrovimab (MK-1654), an investigational monoclonal antibody for the prevention of respiratory syncytial virus (RSV) in infants. In this study, 901 participants were randomized to receive either clesrovimab or the existing RSV treatment, palivizumab. The primary goal of the trial is to assess the safety and tolerability of clesrovimab compared to palivizumab during the first RSV season. Secondary goals include measuring the incidence of RSV-associated lower respiratory infections and hospitalizations through Day 150.

Clesrovimab is designed to offer extended protection against RSV in infants, regardless of their birth weight, and is being tested in both healthy and at-risk infants. RSV is a major cause of respiratory illness in infants and older adults, leading to significant hospitalizations and fatalities worldwide.

Merck, known as MSD outside the U.S. and Canada, is committed to advancing medical research and developing innovative health solutions. The company emphasizes its dedication to using science to improve global health outcomes.

This announcement includes forward-looking statements subject to risks and uncertainties, such as regulatory approvals and market success. Merck does not assume any obligation to update these statements. For further details, refer to Merck's filings with the SEC.